Cannatrek has received Good Manufacturing Practice (GMP) accreditation from the Therapeutic Goods Administration for its Shepparton, Victoria manufacturing facility.
The A$5 million facility is part of a broader planned $17m investment by the company into the Shepparton region including cultivation and end-to-end manufacturing of medicinal cannabis products.
Founder and CEO Tommy Huppert GMP said accreditation was a “major milestone” for the business which will enable it to do more production in-house, give it full control over product quality, and “see more product available to support patients, faster and at a lower cost”.
Cannatrek said it expects to create more than 70 jobs in regional Victoria over the next three years and open up local manufacturing opportunities for both itself and other brands in the industry.
“Through this facility, we are not only generating jobs in the Shepparton area, we are also introducing valuable skills and career paths,” said Huppert.
“Our team members receive extensive training to ensure the production and packaging of pharmaceutical-grade cannabis meet internationally recognised standards.”
The firm added accreditation will also boost export opportunities, with GMP-compliant facilities “more likely to gain acceptance in international markets… where pharmaceutical manufacturers can anticipate facing fewer regulatory barriers or restrictions”.
